Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q
Source: 0001731122-25-000258
Chunk: 91

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q
Item: Part I, Item 8
Chunk 91
---
 Reportable Segment
     
    Description 
  
    RENB (United States)
     
    Developing new immunotherapies to combat cancer 
  
    RENC (Netherlands)
     
    Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection 

The Company’s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the period ending December 31, 2024, there were no significant inter-company revenues or expenses. The chief operating decision
maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported
on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

    Schedule of segment operating loss and asset
    information 

    Operating loss 
    Assets
  
    United States 
    $8,733,302  
    $2,744,766 
  
    Netherlands 
     49,151,567  
     108,595,506 

    $57,884,869  
    $111,340,272 

The chief
operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.

    19

Information
regarding each reportable segment for the three months ended December 31, 2024, is as follows:

    Schedule of information regarding segment reporting 

    RENB 
    RENC 
    Total
  
    General and administrative 
    $3,580,953  
    $772,170  
    $4,353,123 
  
    Research and development 
     161,084  
     —  
     161,084 
  
    Goodwill impairment 
     —  
     —  
     — 
  
    Depreciation and amortization 
     30,529  
     1,580  
     32,109 

    Segment operating loss 
    $3,772,566  
    $773,750  
    $4